Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients-Reference-Cited by-同舟云学术

Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients

Published:2020-08-19 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Omran Mervat M.,Abdelfattah Raafat,Moussa Heba S.,Alieldin Nelly,Shouman Samia A.

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference45 articles.

1. Chronic myeloid leukemia: advances in biology and new approaches to treatment;Goldman;N Engl J Med.,2003

2. Chronic myeloid leukemia: diagnosis and treatment;Quintás-Cardama;Mayo Clin Proc.,2006

3. Chronic myeloid leukemia: a model for oncology;Hehlmann;Ann Hematol.,2005

4. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med.,2002

5. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety;García-Gutiérrez;Front Oncol.,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt;Pharmaceuticals;2024-07-03

2. Contribution of genetic polymorphism in ABCB1 to individual variations of imatinib plasma levels in patients with gastrointestinal stromal tumor;Journal of Gastrointestinal Oncology;2024-04

3. Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring;European Journal of Clinical Pharmacology;2024-03-27

4. Pharmacogenomics of Cancer Chemotherapy: Transporter Polymorphisms and Drug Response;Interdisciplinary Cancer Research;2024

5. Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation;Pharmacogenomics;2023-12